Today: 18 May 2026
US Bond Market’s Fed Week Starts With Yields Rising as Oil Shock Lingers
27 April 2026
2 mins read

US Bond Market’s Fed Week Starts With Yields Rising as Oil Shock Lingers

NEW YORK, April 27, 2026, 05:34 EDT

U.S. Treasury yields climbed early Monday, with investors heading into a Federal Reserve week and crude prices sticking close to $108 a barrel. Persistent jitters from the Middle East kept inflation risk in focus.

The two-year Treasury yield climbed 2.3 basis points, reaching 3.798%, and the 10-year yield tacked on 1.4 basis points to land at 4.323%, according to Tradeweb figures cited by Barron’s. For context, a single basis point equals one-hundredth of a percentage point. Yields tick higher as bond prices retreat.

This shift lands just ahead of the Fed’s two-day meeting, kicking off Tuesday and wrapping with a rate call Wednesday. According to the central bank’s calendar, the April 28-29 session closes out with a 2:30 p.m. press conference on April 29—leaving bond desks tight windows to adjust before Chair Jerome Powell steps up.

Back in March, the Fed kept its target range locked at 3.50% to 3.75%, calling inflation “somewhat elevated.” Governor Stephen Miran broke ranks, pushing for a 25 basis-point cut—a rare dissent that’s become a focal point for traders trying to gauge if the next shift is a rate cut or an extended hold. Federal Reserve

Oil’s the outlier here. Brent crude climbed 2.6% to $108 a barrel. The Strait of Hormuz—crucial for roughly 20% of worldwide oil and gas flows—stayed at the forefront for traders, with prices sensitive to the impasse in U.S.-Iran negotiations and new chatter around a possible reopening of the shipping lane.

ING’s Chris Turner says the Fed can’t call the inflation fight won just yet—not with energy costs climbing and jobs data still solid. Turner expects policymakers could stress the need for rates to remain steady for an extended stretch, a stance that tends to prop up the front end of the Treasury curve.

Hopes for rate cuts are still alive. As of Friday, swaps markets—derivatives used to gauge policy-rate bets—were pricing in roughly a 40% chance the Fed cuts rates before year-end, Bloomberg said; not long ago, that probability sat near 20%. Traders now find themselves balancing growth concerns against the possibility that rising energy prices could stall any Fed easing.

Supply isn’t helping, either. Treasury offering notices put $69 billion in two-year notes up for sale Monday, with competitive bids due by 11:30 a.m. ET. Another $70 billion in five-year notes is on the block, with bids closing at 1:00 p.m. ET.

Pressure remained on the long end too. The 30-year Treasury yield inched up to 4.93% on April 27—just 0.02 percentage point higher than the prior session, Trading Economics data showed. Mortgage rates, corporate financing, and government borrowing all remain expensive.

It wasn’t just U.S. markets feeling the heat. Eurozone yields crept up alongside Treasuries. Over in the UK and Japan, gilts and JGBs tracked the same nervousness, with the European Central Bank, Bank of England, and Bank of Japan all looming large in a packed week for central banks.

The trade can flip fast. Thu Lan Nguyen, who leads FX and commodity research at Commerzbank, pointed out that any market excitement about the chance of Hormuz reopening would probably be “much more muted”—this after earlier optimism fizzled in just a day. An actual reopening could drag oil down and push yields lower; on the flip side, another obstacle could keep the Fed cautious and force bond buyers to hold out for higher yields. Reuters

Latest articles

Quince Therapeutics Stock Faces Nasdaq Pressure After Fresh QNCX Filing

Quince Therapeutics Stock Faces Nasdaq Pressure After Fresh QNCX Filing

18 May 2026
Quince Therapeutics was last quoted at $1.15 before Monday’s Nasdaq open after Nantahala Capital Management disclosed 7.52% beneficial ownership. The company’s latest filing reported no current product candidates and raised substantial doubt about its ability to continue as a going concern. Quince is seeking shareholder approval for another reverse stock split at its June 11 meeting. The company remains out of compliance with Nasdaq’s $50 million market value rule.
Macy’s Gains Pre-Market as Berkshire Buys In — What’s Ahead for Traders

Macy’s Gains Pre-Market as Berkshire Buys In — What’s Ahead for Traders

18 May 2026
Macy’s shares rose in premarket trading after Berkshire Hathaway disclosed a new stake of 3.04 million shares, valued at about $55 million as of March 31. The stock closed Friday at $18.41 and last traded at $18.99 premarket with 128,170 shares exchanged. Macy’s will report first-quarter results on June 3. Tariffs, fuel costs, and weak discretionary spending remain risks for the retailer.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

18 May 2026
ImmunityBio said Monday five U.S. patents protect its Anktiva-plus-BCG bladder cancer treatment through at least 2035, following an exclusive U.S. supply deal with Japan BCG Laboratory. The company plans to seek FDA approval for the Tokyo-172 BCG strain, which is not yet approved in the U.S. ImmunityBio shares last traded at $7.97 before the Nasdaq open.
Why Virax Biolabs Stock Is Jumping Before the Bell Today

Why Virax Biolabs Stock Is Jumping Before the Bell Today

18 May 2026
Virax Biolabs shares jumped in pre-market trading Monday, indicated at $0.3458 after closing Friday at $0.1535. The move followed a sponsored TV segment featuring CEO James Foster and a new SEC filing showing Armistice Capital holds 4.99% of shares. ViraxImmune, the company’s main test, remains in development and is not approved for diagnostic use. No new company press release appeared over the weekend.

Popular

IonQ’s Volatile Week Leaves Bulls Focused on Monday Trade

IonQ’s Volatile Week Leaves Bulls Focused on Monday Trade

18 May 2026
IonQ shares closed Friday at $51.95, down 9.6% for the day but up 5.5% from the prior week. The company reported first-quarter revenue of $64.7 million, up 755% year-over-year, and raised full-year guidance to as much as $270 million. IonQ posted a GAAP net income of $805.4 million but an adjusted EBITDA loss of $96.8 million. Investor focus remains on high spending and cash burn.
Gold Price Forecast: Fed Signal, Iran Talks Put $4,700 Bullion Level Back in Play
Previous Story

Gold Price Forecast: Fed Signal, Iran Talks Put $4,700 Bullion Level Back in Play

Dow Jones Industrial Average Is Lagging — Fed, PCE and Big Tech Could Decide Its Next Move
Next Story

Dow Jones Industrial Average Is Lagging — Fed, PCE and Big Tech Could Decide Its Next Move

Go toTop